Photo of Mark Geyer taken from www.mskcc.org
Feb 2, 2024, 05:57
Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML
Mark Geyer, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, recently shared on X/Twitter:
“Thrilled that Tigen Pharma has formally agreed to partner with us in clinical development of our CD371-targeted IL-18 secreting CAR T-cell product for AML, currently in a phase I study I’m leading at Memorial Sloan Kettering Cancer Center with plans to expand.”
Source: Mark Geyer/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27